ATAD2 Overexpression Identifies Colorectal Cancer Patients with Poor Prognosis and Drives Proliferation of Cancer Cells

Table 2

Univariate and multivariate analyses showing the overall survival in colorectal cancer.

Prognostic parameter	Univariate analysis			Multivariate analysis
	HR	95% CI	value	HR	95% CI	value
ATAD2; (high versus low)	2.272	1.479–3.491	0.000	1.762	1.113–2.790	0.016
Age; (>65 versus ≤65)	1.393	0.911–2.132	0.127	—	—	—
Gender; (male versus female)	1.362	0.905–2.048	0.139	—	—	—
Tumor size; (>5 cm versus ≤5 cm)	1.842	1.201–2.825	0.005	1.698	1.075–2.681	0.023
Tumor location; (colon versus rectum)	0.770	0.497–1.194	0.243	—	—	—
Serum CEA; (>5 ng/mL versus ≤5 ng/mL)	1.628	1.063–2.493	0.025	1.497	0.979–2.291	0.063
Lymph node metastasis (present versus absent)	1.686	1.099–2.588	0.017	1.038	0.644–1.673	0.879
Liver metastasis; (present versus absent)	3.308	1.777–6.151	0.000	1.710	0.777–3.764	0.183
Clinical stage; (I vs. II vs. III vs. IV)	1.983	1.549–2.539	0.000	1.611	1.168–2.221	0.004

HR: hazard ratio; CI: confidence interval. The bold number represents the values with significant differences.